Rusty has been a terrific Board Member and we have benefited greatly from his wisdom and experience. tech ho robert executives accolade adds lighter vet moves launches talent leader capital pr names business geekwire therapeutics We'll provide strategies for finance teams to proactively prepare. The increase in G&A expenses in 2021 was primarily due to increases in personnel-related costs. Well provide future updates regarding the status of Neo-5171 and potential development plans. NYC Wants In-Person Dining Back. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Thank you. I truly value the time Ive spent with Neoleukin and have enjoyed being able to contribute to a successful transition following the merger with Aquinox, said Mr. Alam. The open label Phase 1 trial of NL-201 is currently active at 8 sites in the United States, Australia and Canada. Do you plan on developing NL-201 as a monotherapy in hematologic malignancies? Prior to becoming CFO in February 2018, she served in a series of leadership roles throughout her 20 years with SunTrust, including head of commercial and business banking and CEO of the Atlanta division. Most recently, Ho served as senior finance director at health care company DaVita. While the COVID pandemic has impacted our pipeline development, we now have the space and scientific expertise to make rapid progress. Source: FactSet, Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays.

He is a former Vice President in the Investment Banking Division of Morgan Stanley & Co., where he managed over $9 billion in financing deals and participated in the completion of more than $5 billion in M&A transactions.

Patients with relapsed or refractory solid tumors will receive a standard dose of pembrolizumab combined with ascending doses of NL-201 in order to define a recommended dose and schedule for the combination regimen.

Thanks, Sean. Great, thanks for that color. The data is a preclinical model, multiple myeloma model demonstrate the ability of NL-201 to delay or prevent relapse following autologous stem cell transplant. Priti, you want to comment about the plans for the pembrolizumab combination? Wirth, who has been with the bank for 15 years, will stay on as a senior adviser through the end of the year. This is Mary Kate on for Greg, thanks for taking our question. Next, we plan to initiate a combination of NL-201 and pembrolizumab in patients with advanced solid tumors. Looking forward, we expect a number of upcoming milestones in 2022. Safe Harbor / Forward-Looking StatementsThis press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. We showed that Neo-5171 can withstand acidic environments and is resistant to degradation by common proteases, including pepsin and trypsin. Before joining the drug maker, he held financial and operational leadership roles at American Express and Xerox. [Operator Instructions] Our first question comes from Greg Harrison with Bank of America. Im pleased to share an update on our clinical program. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Bill was previously at Seagen, where he served most recently as Senior Director and Head of Cancer Biology and was previously at Merck and Rosetta Inpharmatics, leading the discovery of oncology targets, predictive biomarkers and synergistic drug combinations. He has served as chief financial officer Jonathan Pruzans right hand since 2009. Following the conclusion of the prepared remarks, we will conduct a question-and-answer session, and instructions will follow at that time. If you have an ad-blocker enabled you may be blocked from proceeding. Maybe as a follow-up, Im wondering at the moment, where do your plans stand for potentially exploring intratumoral delivery? Priti? Its a very exciting time to join Neoleukin, as the company continues to advance its novel technology platform, and Im greatly looking forward to working with this dedicated, talented team, said Mr. Ho. Sure. Eastwood has worked at Thomson Reuters for over 20 years, most recently as senior vice president and head of corporate finance since 2016.Eastwood was formerly chief operating officer of Thomson Reuters Latin America, CFO of the intellectual property and science business, and has also held several senior roles within the finance organization. Were looking forward to the coming months as we progress NL-201 through dose escalation and gather information to help us guide optimal dosing and schedule based on tolerability, pharmacokinetics and pharmacodynamics. First, we expect to report interim Phase 1 dose escalation data on NL-201 in the second half of the year. In the past he held the position of Chief Medical Officer, EVP-Research & Development at Seagen Inc., Chairman & Chief Executive Officer at Aquinox Pharmaceuticals, Inc., Chief Executive Officer of Neoleukin Therapeutics, Inc., Clinical Professor-Medicine at the University of Washington and Medical Director-Umbilical Cord Blood Program at Bloodworks Northwest. Last year, we presented preclinical data demonstrating that NL-201 has synergistic activity when combined with anti-PD-1 therapy, even in checkpoint refractory cancer models. Great, thanks so much. Im very pleased to announce that we also have a new Member of our Board of Directors, Rohan Palekar, who is currently the CEO of 89bio. Julie, please go ahead. Bye. Good afternoon and welcome to Neoleukin Therapeutics year end 2021 conference call. And there is a long history of people using IL-2 as intratumoral treatment, local treatment for melanomas and other accessible tumors. Okay, got it. Bobs deep experience in multiple facets of financial leadership at public companies and financial institutions, including large-scale operations, public offerings, and transactions, will be a great asset to Neoleukin Therapeutics, and we are very pleased to have him join our leadership team, said Jonathan Drachman, M.D., Chief Executive Officer. Thanks, everybody for joining our call today. Rohan has decades of experience in biotechnology in both small and large companies, and has held key leadership positions at J&J and Medivation before becoming CEO of Avanir and subsequently 89bio. The fact that we have such potent IL-15 activity on NK cells suggests that NL-201 could work really well with monoclonal antibodies. Net loss in 2021 was $60.7 million, compared to $33.3 million in 2020. NL-201 was designed using computational methods and then refined through directed evolution and extensive testing in the laboratory. Morgan Stanleys deputy chief financial officer Paul Wirthwill step down from his role at the end of May. Please refer to the companys filings with the SEC which are available from the SEC or in the Neoleukin website for information concerning the risk factors that could affect the company. Perhaps just one more, if you dont mind. Thanks for the question, Charles. And finally, in the second half of 2021, we presented preclinical data at multiple scientific conferences on topics ranging from NL-201 and its effects on the tumor microenvironment to initial data about a novel IL-2 and IL-15 inhibitor molecule. Thanks. And sort of you know what weve seen historically in this space, whether there has been good correlations between some of these PD markers and ultimately the monotherapy clinical activity thats observed. As a reminder, Neoleukin was founded at the end of 2018, went public in August of 2019 through a merger.

Thanks and I have a follow-up. Our future efforts are focused on modifying the biodistribution of this molecule via targeting and/or conditional activation. Before that, Paschal held executive financial, business development, and strategy roles with a number of companies, including Nestl, Godiva, Pillsbury, and Hagen-Dazs. And that requires a lot of follow-up. Learn how Precision Medical leveraged OneWorld to cut the cost of billing in half and added $2.5M in annual revenue.

2021 was a busy year for Neoleukin. So were opening that trial as part of the monotherapy trial. Prior to that, Paschal served more than seven years at fashion company Coach in several executive financial and operating roles, most notably involved in developing Coachs international portfolio. Sources: FactSet, Tullett Prebon, Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements.

Fundamental company data and analyst estimates provided by FactSet. Rohan will be replacing Rusty Williams, who will be stepping off the Board after three years. You know the patient number is really based around some expansion groups that we may want to look at in this setting, renal cell, melanoma, et cetera. Throughout the past year, weve made strides in our research efforts as we explore the range of opportunities that Neoleukins de novo protein technology platform has to offer. Miralles joined CAN in 2011 as senior vice president, treasurer, and head of investments. We are testing two schedules, day 1 every three weeks and day 1 and 8 schedules as monotherapy.

Dukes most recently served as CFO of SunTrust Banks. After our recommended Phase 2 dose and schedule is identified, we plan to enroll indication-specific expansion cohort, including patients with renal cell carcinoma and melanoma. And thanks again for taking my questions. I guess also as a bit of a follow-up to some of the prior questions that have been asked. Thank you. This business guide shares how CFOs from mCloud Technologies, Pact and Quatris Healthco are raising their finance teams profiles and shaping future business decisions. He has built a strong finance department in his time with us and leaves us with an excellent team that will be led by Sean Smith who is joining me on the call today. It is thermodynamically hyperstable, more potent than native IL-2 and preferentially stimulates naive CD8 T cells and NK cells versus immunosuppressive T regulatory cells at low concentrations. We submitted our first IND at the end of 2020 and began a Phase 1 clinical trial in May of 2021. Well be utilizing the sites that we have opened already, 8 plus sites will be open with investigators that are already engaged and familiar with the compound. Sources: FactSet, Dow Jones, ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. Your line is open. Before we start, Id like to remind you that todays call will include forward-looking statements based on current expectations. And weve seen that in our preclinical data.

And now turning to our clinical program NL-201. In addition to Neo-5171, our current discovery stage pipeline includes a T-reg agonist program targeting autoimmune and inflammatory conditions and a next-generation IL-2, IL-15 agonists for oncology indications. Okay. The agreement allows for the evaluation of safety and efficacy of NL-201 in combination with Mercks anti-PD-1 therapy, KEYTRUDA or pembrolizumab in our ongoing Phase 1 trial.

Thanks. Series focused young entrepreneurs making their mark, Revenge of Old World Economy as Big Oils Cash Flow Rivals Tech, Secret Services Own Secrets Come Under Scrutiny in Jan. 6 Probe, Alibaba Added to SEC List of Chinese Firms Facing Delisting, T-Mobile Gets Chance to Mend Airwaves Patchwork in New Auction, Permira Is in Lead to Buy Reorg Research From Warburg Pincus, Creditors Give Zambia Assurances for $1.4 Billion IMF Deal, Levi Strauss Heir Would Join Congresss Richest With NYC Win, Asia Has New Richest Woman as Property Crisis Reshapes Fortunes, Calstrs Posts 1.3% Loss for Latest Fiscal Year After Market Rout, Ticket Bought in Illinois Wins $1.28B Mega Millions Jackpot, Neighbours Finale Episode Draws in Audience of 2.5 Million, Putin, Nukes andKeeping theWest Strong for Ukraine, Trump and His Allies Are In Control of the GOP, Giant Sequoias Are Built to Withstand Fire, But Not These Fires, The Indian Governments Fight Against Fake NewsTargets Political Dissent, Jazzercise Is Alive and Kicking Decades After It Got Started, US Banks Passed the Latest Stress Test, But Are Still Unhappy, Belfast Pride Returns to City Streets for First Time in Three Years, Florida Tells Schools to Disregard Bidens LGBTQ Protections, UAW Head Says Battery-Worker Pay Must Match Assembly Wages, Elon Musks Antics Turn Owners and Would-Be Buyers Against Tesla, House Approves Bill to Help West Fight Wildfires, Drought, Think Your Street Needs a Redesign? It will be available for replay on the Investor Relations section of the Neoleukin website approximately two hours after the call for at least 30 days. Our plans for further development of this program and our early stage pipeline that we are advancing toward potential future clinical evaluation. Before joining Lowes, Mason was vice president, SEC reporting at Bank of America. We know there are other companies in the space are looking, for instance, at the intravesical approach in bladder cancer. News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services. Robert Howill become CFO at biopharmaceutical company Neoleukin Therapeuticson March 16. So maybe not having to start at the very beginning of dose escalation, theres a lot of interests among investigators to start this combination in various tumor types. Copyright 2022 CFO. We use cookies to optimize your experience on our website and for analytics and advertising purposes.

Learn how the CFO's partnership with supply chain managers can address current and future pain points. Please disable your ad-blocker and refresh. Neoleukin Therapeutics, Inc. Well, I think that NL-201 could be a really interesting monotherapy in both in solid tumors and in hematologic malignancies. During our three-year history, Neoleukin has built a state-of-the-art computational and protein engineering research organization. And so I think that its something that were going to learn during the during this process. For starters, we added several key leaders to our Executive Team. So I think you know it is we are trying to get a dose and schedule as quickly as possible and as a result, its all relapse and refractory tumor types in this trial. Sun most recently served as chief financial officer and chief strategy officer at biopharmaceutical company SutroVax. Operator, we can now open the call up for questions. Well, Ill start with the answer. Industry Dive, Inc. (c) 2022, All rights reserved, 1255 23rd Street, NW, Suite 550, Washington, DC 20037, Meta, LendingClub, Verisk, Lazard, Berkeley Lights, Avangrid, Timbers Company, Icertis, TaylorMade Golf Company, Invesco, Neoleukin Therapeutics, Meredith, Viatris, CAN, Morgan Stanley, Thomson Reuters, Comerica, Driven Brands. Copyright FactSet Research Systems Inc. All rights reserved. Data are provided 'as is' for informational purposes only and are not intended for trading purposes. Sean? Kamran Alam, interim CFO of Neoleukin Therapeutics, will continue as a senior strategic advisor to assist in transition activities. By creating completely new molecules, we can optimize multiple parameters, including potency, affinity, stability, size and exactly which parts of the target receptors are engaged. Sure. The increase in net loss, as mentioned, is primarily driven by increased clinical trial expense related to NL-201, increase in personnel costs and costs related to the build out of our headquarters in Seattle, Washington. Cryptocurrencies: Cryptocurrency quotes are updated in real-time. Weve enjoyed connecting virtually with members of the investment and scientific community over the past year and look forward to meeting in person when the opportunity permits. In regards to approaching the NL-201 monotherapy readout expect in the second half of this year. Good afternoon. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. Thats great question. Neoleukin undertakes no obligation to update or revise any forward-looking statements. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. So we actually see the opportunities is very broad and were starting off with monotherapy activity to see what the data look like. Thanks for taking our question. And also the potent effect on T cells could work really well with things like cellular therapy. Thank you. The first-in-human clinical trial of NL-201 is being conducted in patients with relapsed or refractory solid tumors. And you know do you how close do you think youll get to that before you have data to speak of? Meineke franchisor Driven Brandsnamed Tiffany Masonas chief financial officer. Anderson resigned from the company to pursue other opportunities. For more information, please visit the Neoleukin website:www.neoleukin.com. Good afternoon and thank you for joining us today for Neoleukin Therapeutics Conference Call. Private Securities Litigation Reform Act of 1995, including, but not limited to, planned development activities and the potential benefits of the companys product candidates and platform. But those expansions will really be further defined once we get to an RP2D in the combination with KEYTRUDA. Yeah. Your line is open. Thank you for participating. Or do you have a plan maybe an agent in mind that you think makes sense alongside as part of a combination? Our operating cash burn for the year was approximately $50 million after adjusting for non-cash items. There will be some renal cell and melanoma in that mix but theres a wide variety of tumor types in dose escalation. Most recently, Mr. Ho served as Senior Finance Director at DaVita, Inc. a publicly held, Fortune 500 company that is a leading provider of kidney care services in the U.S. In this executive brief based on CFO's June 2022 webinar, you'll learn about the actionable insights CFOs can use to overcome workforce planning challenges amid economic volatility. Were excited for patients and also for the concept of trying to improve upon a proven mechanism of action in IL-2. Your next question comes from Benjamin Burnett with Stifel. Further information on potential risk factors that could affect Neoleukins business and its financial results are detailed under the heading Risk Factors in documents the Company files from time to time with theSecurities and Exchange Commission(SEC), and other reports as filed with theSEC. Before that, he was vice president in the investment banking division of Morgan Stanley. First, Id like to take a moment to acknowledge that Bob Ho will be leaving Neoleukin after two years as our CFO to pursue another opportunity. Experimental results indicate that NL-201 causes expansion of cytotoxic memory CD8 T cells and a decrease in T-regulatory CD4 cells in the murine bone marrow. Your line is open. He was most recently executive vice president and chief risk officer at the insurance company. So there it took a little while to get up and running. | Source: Okay, great. The NL-201 pembrolizumab combination will be tested as a separate arm of the ongoing Phase 1 trial and is expected to begin enrollment by mid-year. Thank you. Neoleukin undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. So I would really think about the data were going to be presenting this year as preliminary and early and really informing what is the potential for NL-201.

Presently, Jonathan G. Drachman holds the position of President, Chief Executive Officer, CFO & Director at Neoleukin Therapeutics, Inc. Dr. Drachman is also on the board of Harpoon Therapeutics, Inc. That is helpful and I think I understand that. You know we expect dose escalation to start at a dose level, and these are learnings from what weve learned in monotherapy. Ho takes over for interim CFO Kamran Alam, who will continue as a senior strategic advisor to assist in the transition. About Neoleukin Therapeutics, Inc.Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity usingde novoprotein design technology. Perhaps you know like we have this extreme clinical benefit longer-term, but may not be as obviously observed early on in something like in early response?

Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) Q4 2021 Earnings Conference Call March 1, 2022 4:30 PM ET, Julie Rathbun - Communications, Investor Relations. But were not expecting that to have a big impact at this point. Finally, the potent effect of IL-15 stimulation on NK cell has the potential to increase ADCC activity in future combinations with the rituximab, daratumumab and other monoclonal antibody. Neoleukins lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. We appreciate the dedicated efforts of our talented team at Neoleukin and remain focused on our overriding goal to advance our de novo protein technology platform to benefit patients with serious diseases, including cancer, inflammation and autoimmune diseases. We have been extremely fortunate to have Kams guidance these past months after the merger of the two companies. Prior to joining CNA, Miralles was the chief financial officer for the investments division of Nationwide Insurance. Hey, I wanted to ask a question about the combination trial with pembrolizumab and sort of enrollment in that trial, enrollment dynamics and what you expect you know in that versus the monotherapy trial, just given the timing issues associated with a monotherapy trial? The Coca-Cola Company, MariaDB, Vistra, Kirklands, Evelo Biosciences, Dynex Capital, Hammitt, Ra Medical Systems. FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Hi there. And so were having a good enrollment and investigator engagement. The so you know our dose escalation is going as we would predict, we havent commented on exactly where we are in terms of dose escalation, but given the potency of the molecule, we would not expect to have to go very far through the process to start seeing at least pharmacodynamic effects of NL-201. NL-201 is a highly potent de novo protein that stimulates both the IL-2 and IL-15 receptors. All rights reserved. Thanks, Priti. I will now ask Priti to talk about our clinical plans. Such statements represent managements judgments, intentions, beliefs and expectations about future events, strategies, product candidates and operating plans. Cortenbach shares how he begins his day with meditation, the Robert Frost quote that inspires him, and his favorite leadership lesson. Great. G&A expenses for the year were $21.5 million, compared to $17.2 million in 2020. Thank you, Julie and good afternoon. In addition, we plan to use information obtained from our solid tumor trial, as well as preclinical data to begin evaluation of NL-201 in hematologic malignancies. He received his Bachelor of Business Administration from the University of Notre Dame and his MBA from the University of Virginia Darden School of Business. Joining me on the call today from Neoleukin are; Jonathan Drachman, CEO; Priti Patel, CMO; and Sean Smith, Vice President, Finance. Today, Id like to discuss our progress with the first-in-human Phase 1 clinical trial of NL-201. In May of last year, we treated our first patient in a Phase 1 clinical trial for NL-201, officially making the transition to become a clinical stage company. We plan to present interim dose escalation data at an appropriate time in the second half of 2022. MediaJulie Rathbun206-769-9219jrathbun@neoleukin.com, InvestorsSolebury TroutBrian Korb646-378-2923bkorb@troutgroup.com, A photo accompanying this announcement is available at:https://www.globenewswire.com/NewsRoom/AttachmentNg/136c9211-7534-4b2c-af0c-d9f8dc6c195e, https://www.globenewswire.com/NewsRoom/AttachmentNg/136c9211-7534-4b2c-af0c-d9f8dc6c195e.

We have good investigator engagements and are enrolling patients quickly. This guide will explore the top risks for your business, including a possible recession, materials shortages and cyber attacks. Prior to Morgan Stanley, he was an associate in the Healthcare Investment Banking Division at Merrill Lynch & Co. Frierott joins the company following a 21-year career at GE, including more than 10 years as a chief financial officer for several of GEs large business units. We also demonstrated that Neo-5171 can be fused to a life half-life extending domain and administered systemically with improved survival of immunosuppressed mice in a graft versus host disease model. I would now like to turn the call over to Julie Rathbun, Communications for Neoleukin Therapeutics. Your line is open. So, we are hoping for positive results. Good afternoon, everyone and thanks for taking my questions. How should we think about where you are in your dose escalation relative to where the potential efficacious window may lie? In May, Dr. Priti Patel joined us as Chief Medical Officer. And last to fall, Bill Arthur joined us as Vice President and Head of Research. This concludes the conference call. In addition, we showed that an NL-201 can turn cold tumors hot, expanding both the absolute number and clonal diversity of tumor-infiltrating T cells and increasing the amounts of interferon gamma and granzyme B produced in the tumor microenvironment. therapeutics

Sitemap 14